EA201991141A1 - Усилители bmp - Google Patents
Усилители bmpInfo
- Publication number
- EA201991141A1 EA201991141A1 EA201991141A EA201991141A EA201991141A1 EA 201991141 A1 EA201991141 A1 EA 201991141A1 EA 201991141 A EA201991141 A EA 201991141A EA 201991141 A EA201991141 A EA 201991141A EA 201991141 A1 EA201991141 A1 EA 201991141A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- bmp
- amplifiers
- formula
- methods
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662420535P | 2016-11-10 | 2016-11-10 | |
| PCT/IB2017/056991 WO2018087677A1 (en) | 2016-11-10 | 2017-11-08 | Bmp potentiators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201991141A1 true EA201991141A1 (ru) | 2019-10-31 |
Family
ID=60569967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201991141A EA201991141A1 (ru) | 2016-11-10 | 2017-11-08 | Усилители bmp |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10259827B2 (OSRAM) |
| EP (1) | EP3538531A1 (OSRAM) |
| JP (1) | JP2019534302A (OSRAM) |
| KR (1) | KR20190075120A (OSRAM) |
| CN (1) | CN109923118A (OSRAM) |
| AR (1) | AR110163A1 (OSRAM) |
| AU (1) | AU2017357719A1 (OSRAM) |
| BR (1) | BR112019009404A2 (OSRAM) |
| CA (1) | CA3043575A1 (OSRAM) |
| EA (1) | EA201991141A1 (OSRAM) |
| MX (1) | MX2019005504A (OSRAM) |
| RU (1) | RU2019117548A (OSRAM) |
| TW (1) | TW201821076A (OSRAM) |
| UY (1) | UY37477A (OSRAM) |
| WO (1) | WO2018087677A1 (OSRAM) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021008824A (es) * | 2019-01-23 | 2021-10-13 | Univ Johns Hopkins | Análogos no inmunosupresores de tacrolimus (fk506) y uso de los mismos. |
| WO2026060005A1 (en) * | 2024-09-10 | 2026-03-19 | Montara Therapeutics, Inc. | Macrocyclic blockers for use in the reduction of peripheral side effects due to everolimus therapy |
| WO2026059989A1 (en) * | 2024-09-10 | 2026-03-19 | Montara Therapeutics, Inc. | Peripheral blockers for central nervous system-selective drug activity |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2799208B2 (ja) | 1987-12-09 | 1998-09-17 | フアイソンズ・ピーエルシー | マクロ環状化合物 |
| EP0378318A1 (en) | 1989-01-11 | 1990-07-18 | Merck & Co. Inc. | Process for synthesis of FK-506 and tricarbonyl intermediates |
| GR1001225B (el) | 1989-09-14 | 1993-06-30 | Fisons Plc | Νέαι μακροκυκλικαί ενώσεις και νέα μέ?οδος χρήσεως τους. |
| GB9014136D0 (en) * | 1990-06-25 | 1990-08-15 | Fujisawa Pharmaceutical Co | Tricyclo compounds,a process for their production and a pharmaceutical composition containing the same |
| DE4028677A1 (de) * | 1990-09-10 | 1992-03-12 | Sandoz Ag | Heteroatome enthaltende, tricyclische verbindungen, verfahren zu ihrer herstellung und ihre verwendung |
| DE4028676A1 (de) * | 1990-09-10 | 1992-03-12 | Sandoz Ag | Heteroatome enthaltende, tricyclische verbindungen, verfahren zu ihrer herstellung und ihre verwendung |
| DE4028666A1 (de) * | 1990-09-10 | 1992-03-12 | Sandoz Ag | Heteroatome enthaltende, tricyclische verbindungen, verfahren zu ihrer herstellung und ihre verwendung |
| DE4028675A1 (de) * | 1990-09-10 | 1992-03-12 | Sandoz Ag | Heteroatome enthaltende, tricyclische verbindungen, verfahren zu ihrer herstellung und ihre verwendung |
| DE4028664A1 (de) * | 1990-09-10 | 1992-03-12 | Sandoz Ag | Heteroatome enthaltende, tricyclische verbindungen, verfahren zu ihrer herstellung und ihre verwendung |
| CA2071332A1 (en) * | 1991-06-25 | 1992-12-26 | Laszlo R. Treiber | C-21 hydroxylated fk-506 antagonist |
| GB9202196D0 (en) | 1992-02-01 | 1992-03-18 | Fisons Plc | Method of treatment |
| US5284877A (en) * | 1992-06-12 | 1994-02-08 | Merck & Co., Inc. | Alkyl and alkenyl macrolides having immunosuppressive activity |
| GB9218597D0 (en) | 1992-08-25 | 1992-10-14 | Fisons Plc | Novel method of treatment |
| GB9218027D0 (en) | 1992-08-25 | 1992-10-14 | Fisons Plc | Novel method of treatment |
| US7109317B1 (en) * | 1998-11-06 | 2006-09-19 | President And Fellows Of Harvard College | FK506-based regulation of biological events |
| WO2000058318A1 (en) | 1999-03-31 | 2000-10-05 | Abbott Laboratories | Phosphate containing macrocyclic immunomodulators |
| US6569867B2 (en) | 1999-10-01 | 2003-05-27 | Kosan Biosciences, Inc. | Polyketide derivatives |
| CA2407259A1 (en) | 2000-05-17 | 2001-11-22 | Chaitan Khosla | Polyketide derivatives |
| CA2514733A1 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| TW200637552A (en) * | 2005-01-20 | 2006-11-01 | Array Biopharma Inc | Macrocyclic analogs for the treatment of immunoregulatory disorders and respiratory diseases |
| WO2012047762A2 (en) | 2010-10-08 | 2012-04-12 | Amplyx Pharmaceuticals, Inc. | Antifungal agents |
| WO2015106283A1 (en) * | 2014-01-13 | 2015-07-16 | Amplyx Pharmaceuticals, Inc. | Antifungal compounds |
-
2017
- 2017-11-08 WO PCT/IB2017/056991 patent/WO2018087677A1/en not_active Ceased
- 2017-11-08 BR BR112019009404A patent/BR112019009404A2/pt not_active Application Discontinuation
- 2017-11-08 MX MX2019005504A patent/MX2019005504A/es unknown
- 2017-11-08 EA EA201991141A patent/EA201991141A1/ru unknown
- 2017-11-08 JP JP2019524240A patent/JP2019534302A/ja not_active Ceased
- 2017-11-08 RU RU2019117548A patent/RU2019117548A/ru not_active Application Discontinuation
- 2017-11-08 EP EP17808588.2A patent/EP3538531A1/en not_active Withdrawn
- 2017-11-08 CA CA3043575A patent/CA3043575A1/en not_active Abandoned
- 2017-11-08 KR KR1020197016038A patent/KR20190075120A/ko not_active Withdrawn
- 2017-11-08 TW TW106138532A patent/TW201821076A/zh unknown
- 2017-11-08 CN CN201780069068.7A patent/CN109923118A/zh active Pending
- 2017-11-08 US US15/807,462 patent/US10259827B2/en active Active
- 2017-11-08 AU AU2017357719A patent/AU2017357719A1/en not_active Abandoned
- 2017-11-09 AR ARP170103119A patent/AR110163A1/es unknown
- 2017-11-09 UY UY0001037477A patent/UY37477A/es not_active Application Discontinuation
-
2019
- 2019-02-26 US US16/286,002 patent/US20190194227A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2019117548A (ru) | 2020-12-10 |
| KR20190075120A (ko) | 2019-06-28 |
| US20190194227A1 (en) | 2019-06-27 |
| MX2019005504A (es) | 2019-08-12 |
| CA3043575A1 (en) | 2018-05-17 |
| TW201821076A (zh) | 2018-06-16 |
| UY37477A (es) | 2018-06-29 |
| EP3538531A1 (en) | 2019-09-18 |
| US20180127436A1 (en) | 2018-05-10 |
| WO2018087677A1 (en) | 2018-05-17 |
| JP2019534302A (ja) | 2019-11-28 |
| US10259827B2 (en) | 2019-04-16 |
| AR110163A1 (es) | 2019-02-27 |
| BR112019009404A2 (pt) | 2019-07-30 |
| AU2017357719A1 (en) | 2019-05-16 |
| CN109923118A (zh) | 2019-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123475T1 (el) | Αναστολεις της ειδικης για λυσινη απομεθυλασης-1 | |
| CY1125127T1 (el) | Αναστολεις λυσινης ειδικης απομεθυλασης-1 | |
| MX389672B (es) | Inhibidores de ssao de aminopirimidina | |
| EA201791420A1 (ru) | Соединения триазолопиримидина и их применения | |
| CL2017001566A1 (es) | Derivados de azabiciclootano como agonistas de fxr para el uso en el tratamiento de enfermedades hepáticas y gastrointestinales. | |
| EA201891024A1 (ru) | Соединения-ингибиторы tank-связывающей киназы | |
| EA201791304A1 (ru) | Производные изохинолина для лечения вич | |
| EA201790407A1 (ru) | Зонды для визуализации белка хантингтина | |
| EA201692203A1 (ru) | Соединения, ингибирующие tank-связывающую киназу | |
| EA201790395A1 (ru) | Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы | |
| MX373373B (es) | Inhibidores de desmetilasa-1 específica de lisina. | |
| MX381487B (es) | Ciertos inhibidores de la proteina quinasa. | |
| JO3654B1 (ar) | مركبات ازا بنزيميدازول واستخدامها كمعدلات للمستقبلات ذات النمط الإمبائي (ampa) | |
| EA201791684A1 (ru) | Селективные ингибиторы bace1 | |
| EA201891644A1 (ru) | Антибактериальные соединения и их применение | |
| EA201790432A1 (ru) | Зонды для визуализации белка хантингтина | |
| MX376283B (es) | Compuestos de imidazopiridazina. | |
| MX2019007339A (es) | Compuestos de pirazolopirimidina y metodos de uso de los mismos. | |
| CY1123406T1 (el) | Παραγωγο τριαζολοπυραζινονης χρησιμο ως ενας ανθρωπινος pde1 αναστολεας | |
| EA201790400A1 (ru) | Зонды для визуализации белка хантингтина | |
| EA201790408A1 (ru) | Зонды для визуализации белка хантингтина | |
| CY1124413T1 (el) | Ανταγωνιστες του υποδοχεα cgrp | |
| EA201992360A1 (ru) | Кристаллические формы (s)-афоксоланера | |
| MX378739B (es) | Compuestos de 2-oxindol. | |
| EA201991595A1 (ru) | Активатор nrf2 |